A Pilot Study of the TearCare System in Adults With Dry Eye Disease

Not Applicable

Completed

Conditions: Dry Eye

Registration Number: NCT03006978

Lead Sponsor: Sight Sciences, Inc.

Brief Summary: This is a small, pilot study intended to determine the feasibility of this product.

Detailed Description: The objective of this study was to evaluate the safety and effectiveness of the TearCare® System in adult patients with clinically significant dry eye disease (DED). This was a prospective, single-center, randomized, parallel-group, clinical trial. Subjects with DED were randomized to either a single TearCare treatment conducted at the clinic or 4 weeks of daily warm compress (WC) therapy. The TearCare procedure consisted of 12 minutes of thermal eyelid treatment immediately followed by manual expression of the meibomian glands. WC therapy consisted of once daily application of the compresses to the eyelids for 5 minutes. Subjects were followed until 6 months post-treatment.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 24

Inclusion Criteria

At Least 18 Years of age
Reports dry eye symptoms within 3 months of the screening exam with a SPEED score >=6
Schirmer 1 value of <10 mm in at least one eye or a Tear Breakup time <10 seconds in at least one eye
Willing to comply with the study, procedures, and follow-up
Willing and able to provide consent

Exclusion Criteria

Any active ocular or peri-ocular infection or inflammation
Recurrent eye inflammation within the past 3 months
Ocular surgery, oculoplastic surgery, ocular injury, Ocular Herpes Simplex, or Herpes Zoster
Ocular surface abnormalities that may affect tear film distribution or treatment
Abnormal eyelid function in either eye
Diminished or abnormal facial, periocular, ocular or corneal sensation
Ocular surface abnormalities such as corneal epithelial defects, ulcers, corneal dystrophies
Systemic diseases resulting in dry eye (e.g. Sjogren's syndrome)
Allergies to silicone tissue adhesives
An absence or fibrosis of the Meibomian glands (e.g. ectodermal dysplasia).
Unwillingness to abstain for the duration of the study from systemic medication known to cause ocular dryness (e.g. Accutane, antihistamines, etc.)
Anyone who requires chronic use (i.e. for any portion of the study) of topical ophthalmic antibiotics, steroids, non-steroidal anti-inflammatory medications or who has been on any of these medications within the past 30 days.
Unwillingness to washout and remain off certain dry eye medications for the duration of the study.
Participation in another ophthalmic clinical trial within the past 30 days
Co-existing conditions that could interfere with the assessment of safety or efficacy of treatment (e.g. macular disease, pregnancy, nursing, etc.)

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Mean Change in Tear Breakup Time From Baseline to Month 1	4 weeks	The TBUT was evaluated by measuring the time to breakup of the tear film following a complete blink when viewed through the slit-lamp using a cobalt blue filter. The TBUT was recorded using a stopwatch for each eye as the average of 3 measurements at each visit. The change in TBUT was The difference between the mean baseline value and the mean Month 1 value. The TBUT for each eye for a subject was averaged. An increase in TBUT represents an improvement.

Secondary Outcome Measures

Name	Time	Method
Mean Change in Meibomian Gland Score From Baseline to Month 1	1 month	Using a Korb Meibomian Gland Evaluator (TearScience), the meibomian gland assessment was conducted by evaluating the consistency of the secretions that were observed upon expression of meibomian glands in the nasal, central, and temporal regions of the lower eyelids. The central, consecutive 5 glands in each region were evaluated. The instrument was held at the eyelid margin for 10-15 seconds, and the secretions were graded on a 0-3 scale for each gland (0=no expression; 1=toothpaste; 2=cloudy; and 3=clear), with a 0-45 score range for each eye. The score for each eye of a subject was averaged. The change from baseline in the Meibomian Gland Score is the difference between the mean baseline value and the mean value at Month 1. A higher score represents an improvement.
Change in SPEED (Standard Patient Evaluation of Eye Dryness) Questionnaire Score From Baseline	1 Month	The Standard Patient Evaluation for Eye Dryness (SPEED) questionnaire is a well-validated instrument and widely used assessment tool for dry eye indications. The SPEED questionnaire was used to evaluate 4 symptoms (1-dryness, grittiness, or scratchiness, 2-soreness or irritation, 3-burning or watering, 3-eye fatigue) of study subjects. The maximum score is 28 (worst) and the minimum possible is 0 (best). The SPEED survey measures the severity (0-4 scale - each symptom) and frequency (0-3 scale - each symptom) of these DED symptoms. The SPEED score was calculated by adding the total of the frequency and severity scores; a score of greater than or equal to 6 may be an indicator of DED. The reported value is the mean of the change for all subjects. A negative result indicates improvement.
Mean Change in OSDI Score From Baseline to Month 1	1 Month	The Ocular Surface Disease Index (OSDI) is a 12-item questionnaire that assesses symptoms of ocular irritation associated with dry eye and the impact of these on vision-related activities. The OSDI score ranges from 0 (best possible) to 100 (worst possible). The change in OSDI questionnaire from baseline to Month 1 is the difference between the scores at the two timepoints. A negative value would indicate improvement and a positive value, a worsening. The reported value is the mean of the change for all subjects.
Mean Change in SANDE ( Symptom Assessment in Dry Eye) Questionnaire Score From Baseline to Month 1	1 Month	The SANDE instrument is a simple 2-item questionnaire, that focuses on the frequency and the severity of dry eye symptoms with each measured along a visual analog scale. SANDE, because of its simplicity, is often used in routine clinical practice. For the core questions, the frequency and severity scores are multiplied together, and the square root is taken to produce an overall SANDE score from 0 (best possible) to 100 (worst possible). The mean change from baseline to month 1 is the difference in the two scores. A negative result indicates improvement.

Trial Locations

Locations (1): Central Eye Care, Ltd.
🇺🇸
Arlington Heights, Illinois, United States
Central Eye Care, Ltd.
🇺🇸Arlington Heights, Illinois, United States